COMMUNIQUÉS West-GlobeNewswire

-
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
30/07/2025 -
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
30/07/2025 -
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
30/07/2025 -
KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy
30/07/2025 -
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
30/07/2025 -
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
30/07/2025 -
Leading European Shipbuilder Selects Aino’s SaaS Platform
30/07/2025 -
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025 -
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
30/07/2025 -
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
30/07/2025 -
Clenbuterol for Sale: The Complete Guide to Buying Real Clen Pills Online Without Getting Scammed
30/07/2025 -
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
30/07/2025 -
Communiqué de presse: Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis
30/07/2025 -
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
30/07/2025 -
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
30/07/2025 -
J-Star Holding Announces Pricing of $5.0 Million Initial Public Offering
30/07/2025 -
Investor Confidence Shaken as Senegal Detains Oil Executive and Philanthropist Khadim Ba Amid Global Outcry
30/07/2025 -
Telix H1 2025 Results: Investor Webcast Notification
30/07/2025 -
Rakovina Therapeutics Announces Stock Option Grants
29/07/2025
Pages